Naurex Inc. Reports Positive Top-Line Phase I Results For Its Novel Mechanism NMDA Receptor Modulator GLYX-13 In Treatment-Resistant Depression
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13. GLYX-13 is a GFPA selective modulator of the NMDA receptor. It is initially being developed as a therapy for treatment-resistant depression in severely depressed patients. In the Phase I trial, adverse events were similar for subjects receiving GLYX-13 and placebo and were all rated as mild. There were no signs of the schizophrenia-like side effects associated with other NMDA receptor modulator drugs.
People who spend a lot of time browsing the net are more likely to show depressive symptoms, according to the first large-scale study of its kind in the West by University of Leeds psychologists. Researchers found striking evidence that some users have developed a compulsive internet habit, whereby they replace real-life social interaction with online chat rooms and social networking sites. The results suggest that this type of addictive surfing can have a serious impact on mental health. Lead author Dr Catriona Morrison, from the University of Leeds, said: "The internet now plays a huge part in modern life, but its benefits are accompanied by a darker side.
Innovative neuroscience research and expanded clinical care have been launched at the new Center of Excellence on Mood Disorders at The University of Texas Medical School at Houston. "New research here is trying to pinpoint the neurobiological mechanisms involved in mood disorders, " said Jair Soares, M.D., co-director of the center and chairman of the Department of Psychiatry and Behavioral Sciences at The University of Texas Medical School at Houston. "We need to link those discoveries to a better way to treat the disease. In the new center, we'll be able to combine high-level care with research." According to the National Institute of Mental Health (NIMH), 9.
Many clinicians believe that depression goes hand in hand with cognitive difficulties such as memory problems or difficulties concentrating and paying attention, but a recent review of nearly 20 years of literature conducted by researchers from UT Southwestern Medical Center has found that depression does not always lead to such impairments. "The relationship between cognition thinking, attention and memory and depression remains poorly understood from a neuroscientific standpoint, " said Dr. Munro Cullum, chief of psychology at UT Southwestern and senior author of the review appearing in the January issue of Neuropsychology, a journal published by the American Psychological Association.
Meg McArthur, from Breakthrough Breast Cancer, says: "This research is welcome because it gives an insight into how the effectiveness of tamoxifen could be influenced by taking antidepressants. Tamoxifen remains a beneficial treatment for breast cancer and as several antidepressants are available doctors should be able to find the right combination for patients. "This should not put patients off taking tamoxifen and any concerns should be discussed with their doctor." Source Breakthrough Breast Cancer
Scientists at Emory University School of Medicine have discovered unexpected properties for a precursor to melatonin, the hormone that regulates sleep cycles. Melatonin is produced from the neurotransmitter serotonin in a daily rhythm that peaks at night. Melatonin's immediate precursor, N-acetylserotonin, was not previously thought to have effects separate from those of melatonin or serotonin. Now an Emory team has shown that N-acetylserotonin can stimulate the same circuits in the brain activated by the growth factor BDNF (brain-derived neurotrophic factor). The results will be published online this week in the Proceedings of the National Academy of Sciences.